Literature DB >> 19661363

Kidney-autotransplantation before radiotherapy: a case report.

Tobias Bölling1, Kirsten Janke, Heiner H Wolters, Marco Glashörster, Iris Ernst, Normann Willich, Jens Brockmann, Stefan Könemann.   

Abstract

BACKGROUND: A 28-year-old man suffering from a Ewing tumour arising from the 9th-11th ribs with infiltration of neuroforamina without distant metastases was planned to receive radiotherapy following primary intralesional surgery and induction chemotherapy. Due to pleural infiltration and effusion, a hemithorax irradiation with a sequential boost to the primary tumour site had to be administered. Different treatment planning variants failed to provide sufficient radiotherapy planning in view of target volume coverage and avoidance of organs at risk, especially due to high calculated radiation doses potentially compromising the left kidney.
MATERIALS AND METHODS: To prevent left kidney organ exposure, an autotransplantation of the left kidney into the right fossa iliaca was performed. An infiltration of the kidney was initially excluded.
RESULTS: Postoperatively, a renal scintigraphy showed a normal function of both kidneys allowing sufficient radiotherapy treatment planning. Target volume coverage was easily obtained using a combination of hemithorax irradiation and a sequential boost by an intensity-modulated-radiotherapy technique.
CONCLUSION: In difficult individual treatment situations, surgical transpositions as well as organ autotransplantation might be useful in reducing radiotherapy organ dose levels.

Entities:  

Mesh:

Year:  2009        PMID: 19661363

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

Review 1.  Kidney Autotransplantation: Between the Past and the Future.

Authors:  Mahmoud Alameddine; Zhobin Moghadamyeghaneh; Ali Yusufali; Alexa Marie Collazo; Joshua S Jue; Ian Zheng; Mahmoud Morsi; Nachiketh Soodana Prakash; Javier Gonzalez
Journal:  Curr Urol Rep       Date:  2018-02-05       Impact factor: 3.092

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.